FDA approval for ROIV’s LISRAYA dermatomyositis therapy
FDA approves LISRAYA as the first targeted oral therapy for dermatomyositis, with launch immediately.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.